



# Medical Policy

Policy:	<b>94057</b>	Initial Effective Date:	<b>12/05/1994</b>
SUBJECT:	<b>Light Therapies for Dermatological Conditions</b>	Annual Review Date:	<b>04/24/2017</b>
	- <b>Phototherapy</b>	Last Revised Date:	<b>10/22/2018</b>
	- <b>Photochemotherapy</b>		
	- <b>Laser Therapy</b>		

**Prior approval is required for some or all procedure codes listed in this Corporate Medical Policy.**

**Some or all procedure codes listed in this Corporate Medical Policy may be considered experimental/investigational.**

**Definitions:** *Phototherapy (actinotherapy)* refers to light source ultraviolet (UV) irradiation of skin by either ultraviolet A (UVA 320-400 nm) or ultraviolet B (UVB 295-320 nm) without the concomitant use of photochemotherapeutic agents or drugs.

*Photochemotherapy* involves application of a topical agent to the targeted skin area or systemic administration of a drug prior to exposure to a UVA or UVB light source.

Photochemotherapy includes the following:

- Topical tar or petrolatum in combination with ultraviolet B (Goeckerman treatment) therapy; or
- Oral or topical psoralen in combination with ultraviolet A (PUVA) therapy.

*Laser therapy* involves use of a hand-held, high energy, excimer laser light source to generate UVB radiation at a wavelength of 308 nm to target focal skin lesions. Laser therapy permits administration of larger doses of UVB radiation to specific areas with less exposure to surrounding, uninvolved skin.

**Medical Necessity:**

**A. Phototherapy:** The Company considers phototherapy (actinotherapy) (CPT Code 96900) medically necessary and eligible for reimbursement providing that one of the following medical criterion is met:

- Generalized skin involvement, refractory to conservative conventional medical therapy

**AND**

**At least one** of the following clinical conditions is present:

This document is subject to the disclaimer found at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>. If printed, this document is subject to change. Always verify with the most current version of the official document at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>.



# Medical Policy

- Mycosis fungoides
- Sézary's disease
- Other atopic dermatitis and related conditions
- Contact dermatitis and other eczema; unspecified cause
- Other psoriasis
- Parapsoriasis
- Pityriasis rosea
- Lichen planus
- Pruritus of genital organs
- Intractable pruritus from liver or kidney disease
- Prurigo nodularis
- Unspecified pruritic disorder
- Other specified diseases of hair and hair follicles
- Other specified anomalies of skin
- Vitiligo of sun exposed skin

**Home phototherapy:** The Company considers use of a home phototherapy unit (**HCPCS Codes A4633, E0691, E0692, E0693 and E0694**) **medically necessary** and eligible for reimbursement providing that the above phototherapy medical criterion is met in the presence of *all* of the following:

- Phototherapy treatment has demonstrated efficacy for the previous one month or longer; and
- Phototherapy treatment is expected to be required indefinitely; and
- Ongoing physician supervision is present, including periodic examinations and regular monitoring; and
- Either frequent phototherapy treatments ( $\geq 2$  per week) are required or office visits for phototherapy treatments are not feasible or would be unduly burdensome (e.g., remote location, homebound status)

**AND**

**At least one** of the following clinical conditions is present:

- Mycosis fungoides
- Sézary's disease
- Other atopic dermatitis and related conditions
- Contact dermatitis and other eczema; unspecified cause
- Other psoriasis
- Parapsoriasis
- Pityriasis rosea
- Lichen planus



# Medical Policy

- Pruritus of genital organs
- Intractable pruritus from liver or kidney disease
- Prurigo nodularis
- Unspecified pruritic disorder
- Other specified diseases of hair and hair follicles
- Other specified anomalies of skin

**NOTE:** The Company considers use of a home phototherapy unit (**HCPCS Codes A4633, E0691, E0692, E0693 and E0694**) for treatment of clinical conditions not listed above **investigational** and **not** eligible for reimbursement.

Benefits for investigational services are subject to each specific benefit plan.

## B. Photochemotherapy:

- **Ultraviolet B:** The Company considers photochemotherapy using tar and ultraviolet B (Goeckerman treatment) therapy or petrolatum and ultraviolet B therapy (**CPT Codes 96910 and 96913**) **medically necessary** and eligible for reimbursement providing that the following medical criterion is met:

1. Generalized, intractable disease, refractory to conservative standard medical therapy;

**AND**

*At least one* of the following clinical conditions is present:

- Mycosis fungoides
- Other erythematosquamous dermatosis
- Other atopic dermatitis and related conditions
- Contact dermatitis and other eczema; unspecified cause
- Psoriatic arthropathy
- Other psoriasis
- Parapsoriasis
- Lichen planus
- Pruritus of genital organs
- Intractable pruritus from liver or kidney disease
- Unspecified pruritic disorder
- Mastocytosis
- Granuloma annulare
- Vitiligo of sun exposed skin



# Medical Policy

- **Ultraviolet A (PUVA):** The Company considers photochemotherapy using psoralens and ultraviolet A (CPT Codes 96912 and 96913) **medically necessary** and eligible for reimbursement providing that the following medical criterion is met:

1. Generalized skin involvement, refractory to conservative standard medical therapy;

**AND**

*At least one* of the following clinical conditions is present:

- Mycosis fungoides
- Sézary's disease
- Malignant mast cell tumors
- Mastocytosis
- Other lymphomas
- Regional enteritis; unspecified site
- Other atopic dermatitis and related conditions
- Contact dermatitis and other eczema; unspecified cause
- Subcorneal pustular dermatosis
- Other specified bullous dermatoses
- Other specified erythematous conditions
- Other psoriasis
- Parapsoriasis
- Lichen planus
- Pruritus of genital organs
- Intractable pruritus from liver or kidney disease
- Lichenification and lichen simplex chronicus
- Other specified pruritic conditions
- Unspecified pruritic disorder
- Circumscribed scleroderma
- Alopecia
- Systemic sclerosis
- Other specified anomalies of skin
- Complications of transplanted organ
- Vitiligo of sun exposed skin



# Medical Policy

**C. Laser therapy:** The Company considers laser therapy (CPT Codes 96920, 96921, 96922 and 96999\*) **medically necessary** and eligible for reimbursement providing that *at least one* of the following medical criteria are met:

- Vitiligo refractory to conventional medical therapy, narrow-band ultraviolet B phototherapy and/or psolarens and ultraviolet A light therapy (PUVA); **OR**
- Mild to moderate, localized, plaque psoriasis affecting body area  $\leq 10\%$ ; and
- Failure of, intolerance to or unable to receive a  $\geq 3$  *month* course of standard topical medical therapy, including *at least three* of the following:
  1. Topical corticosteroids (e.g., fluocinonide cream, betamethasone dipropionate ointment); or
  2. Vitamin D derivatives (e.g., calcipotriene); or
  3. Retinoids (e.g., tazarotene); or
  4. Anthralin; or
  5. Tar preparations; and/or
  6. Keratolytic agents (e.g., salicylic acid, lactic acid, urea);

**AND**

*At least one* of the following clinical conditions is present:

- Vitiligo of sun exposed skin
- Psoriasis

**Frequency limitations:** The frequency of laser therapy for the treatment of **psoriasis** is limited to three episodes of care within a 365 day period. Each care episode should consist of  $\leq 10$  laser treatments. Additional laser therapy for conditions refractory to the initial three episodes of care is considered **not medically necessary** and **not** eligible for reimbursement.

The frequency of laser therapy for the treatment of **vitiligo** is limited to three months treatment with eight to ten sessions per month. The Company will provide continuation of coverage for excimer laser therapy for treatment of vitiligo for an additional three months if documentation demonstrates at least moderate repigmentation over the previous three month period.

**\*NOTE: CPT Code 96999 (unlisted special dermatological service or procedure) should be used for reimbursement of excimer laser therapy for treatment of vitiligo.**



# Medical Policy

## **Documentation Requirements:**

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

**Prior approval is required for CPT Codes 96920, 96921, 96922, 96999<sup>†</sup> HCPCS Codes A4633, E0691, E0692, E0693 and E0694.**

**<sup>†</sup>When unlisted special dermatological service or procedure (96999) is determined to be laser therapy for treatment of vitiligo.**

**HCPCS Codes A4633, E0691, E0692, E0693 and E0694 are considered investigational and not eligible for reimbursement when home phototherapy is determined to be for treatment of vitiligo.**



# Medical Policy

## Sources of Information:

- Alikhan, A., Felsten, L. M., Daly, M., & Petronic-Rosic, V. (2011). Vitiligo: a comprehensive overview. *J Am Acad Dermatol*, 65(3), 473-491
- American Academy of Dermatology. (2010). *Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy*. Retrieved from <https://www.aad.org/File%20Library/Global%20navigation/Education%20and%20quality%20care/section6-psoriasis-guideline.pdf>.
- American Academy of Dermatology. (2014). *Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents*. Retrieved from <http://www.guideline.gov/content.aspx?id=48410&search=phototherapy>
- Centers for Medicare & Medicaid Services.
  - Durable medical equipment reference list (280.1). National coverage determination. Effective date May 05, 2005.
  - Laser procedures (140.5). National coverage determination. Effective date May 01, 1997.
  - Treatment of psoriasis (250.1). National coverage determination. Effective date not posted.
- Feldman, S. R., Mellen, B. G., Housman, T. S., Fitzpatrick, R. E., Geronemus, R. G., Friedman, P. M., ... Morison, W. L. (2002). Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. *J Am Acad Dermatol*, 46(6), 900-906.
- Goldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, & Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. *J Eur Acad Dermatol Venereol*, 21(4), 504-508.
- Grubb, B. (2008). Treating vitiligo and psoriasis with the excimer laser. *JAAPA*, 21(12), 53-54.
- Hamzavi, I., & Lui, H. (2005). Using light in dermatology: an update on lasers, ultraviolet phototherapy and photodynamic therapy. *Dermatol Clin*, 23(2), 199-207.
- Hayes, Inc., Lansdale, PA: Author.
  - *Laser therapy for psoriasis*. (2013, November 19). Annual Review (2016, October 13).
- Hofer, A., Haassan, A. S., Legat, F. J., Kerl, H., & Wolf, P. (2006). The efficacy of excimer laser (308 nm) for vitiligo at different body sites. *J Eur Acad Dermatol Venereol*, 20(5), 558-564.
- Jin, Y., Mailloux, C. M., Gowan, K., Riccardi, S. L., LaBerge, G., Bennett, D. C., ... Spritz, R. A. (2007). NAPL1 in vitiligo-associated multiple autoimmune disease. *N Engl J Med*, 356(12), 1216-1225.
- Kollner, K., Wimmershoff, M. B., Hintz, C., Landthaler, M., & Hohenleutner, U. (2005). Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis. *Br J Dermatol*, 152(4), 750-754.
- Lilly, E., Lu, P.D., Borovicka, J.H., Victorson, D., Kwasny, M.J., West, D.P., & Kundu, R. (2013). Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). *J Am Acad Dermatol* 69(1) e11-e18.
- Morison, W. L., Atkinson, D. F., & Werthman, L. (2006). Effective treatment of scalp psoriasis using the excimer (308 nm) laser. *Photodermatol Photoimmunol Photomed*, 22(4), 181-183.
- National Institute for Health and Clinical Excellence. (2012, October). *Clinical Guidance 153. Psoriasis: assessment and management*. Retrieved from <https://www.nice.org.uk/guidance/cg153>
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. *Health information. Psoriasis. Questions and answers about psoriasis*. Retrieved from [http://www.niams.nih.gov/Health\\_Info/Psoriasis/](http://www.niams.nih.gov/Health_Info/Psoriasis/)
- Stern, R. S. (2007). Psoralen and ultraviolet a light therapy for psoriasis. *N Engl J Med*, 357(7), 682-690.

This document is subject to the disclaimer found at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>. If printed, this document is subject to change. Always verify with the most current version of the official document at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>.



# Medical Policy

<b>Applicable Code(s)</b>	
<b>CPT Codes:</b>	<b>96900, 96910, 96912, 96913, 96920, 96921 and 96922</b>
<b>HCPCS Codes :</b>	<b>A4633, E0691, E0692, E0693 and E0694</b>

This document is subject to the disclaimer found at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>. If printed, this document is subject to change. Always verify with the most current version of the official document at <http://www.medmutual.com/provider/MedPolicies/Disclaimer.aspx>.